NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines
Medicines Update Oncology

New WOSCAN protocols (August 2016)

The following West of Scotland Cancer Network (WOSCAN) protocols have been prepared in response to national guidance and are now available on the WOSCAN intranet site (NHS network access required):

 

Bevacizumab in combination with paclitaxel, for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.  

  • For protocol click here. Please note: the paclitaxel schedule in this protocol is out with the licensed schedule but clinical data and experience has demonstrated that patients tolerate this schedule better whilst retaining efficacy and response to treatment 
  • The GGC formulary entry has been updated. Click here
  • For relevant SMC advice click here

 

Trastuzumab in combination with capecitabine or fluorouracil and cisplatin for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastrooesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. It is indicated for use only in patients with metatstatic gastric cancer whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory FISH+ result, or IHC 3+, as determined by an accurate and validated assay

  • For protocol click here
  • The GGC formulary entry has been updated. Click here
  • For relevant SMC advice click here

 

Enzalutamide for the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated

  • For protocol click here
  • The GGC formulary entry has been updated. Click here
  • For relevant SMC advice click here

 

Ceritinib for ALK positive advanced NSCLC previously treated with crizotinib

  • For protocol click here
  • The GGC formulary entry has been updated. Click here
  • For relevant SMC advice click here